Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Investing.com - Barclays has assumed coverage on Cytokinetics (NASDAQ:CYTK) with an Overweight rating and a price target of $87.00, representing 36% upside from the current price of $64.01. The stock ...

In the EXAKT study from the U.K., the home-use pulse oximeters assessed all gave higher oxygen saturation (SpO2) readings for patients with darker skin tones than for patients with lighter skin tones.

A total of 11,018 paired SpO2-SaO2 measurements were analysed. All five pulse oximeters returned higher SpO2 values for patients with darker skin tones than patients with lighter skin tones, at any ...

NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the ...

NASHVILLE, Tenn. -- Racial biases persist in the use of pulse oximetry devices for patients with acute hypoxemic respiratory failure (AHRF) requiring very high levels of oxygen support, a ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve ...

“This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives,” ...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical ...

Investing.com - H.C. Wainwright has reiterated its Buy rating and $120.00 price target on Cytokinetics (NASDAQ:CYTK), representing a significant upside from the current price of $53.89. According to ...

Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...